Skip to main content
2024 Guide to Patient Support Services

Bayer

2024 PSS Guide

Bayer Oncology Support Programs

Zero Co-Pay Program
Access Services by Bayer

Bayer offers drug-specific programs to assist patients with access and resources. A complete list of Bayer oncology products and their related assistance programs is provided in the Table.

Bayer Oncology Support Programs

Aliqopa Resource Connections

The Aliqopa Resource Connections, or ARC Program, offers comprehensive access, reimbursement support, and patient assistance services to patients taking Aliqopa to include:

  • Bayer US Patient Assistance Foundation for qualified uninsured or underinsured patients
  • Temporary Patient Assistance Program for patients whose coverage is delayed or who experience a temporary lapse in coverage for Aliqopa
  • Aliqopa $0 Co-Pay Program for eligible patients with commercial insurance.

To learn more or to enroll your patient in the ARC Program, call 833-254-7672 or visit Aliqopa Resource Connections.

Access Services by Bayer

Access Services by Bayer is a free support program available to eligible patients who have been prescribed Nexavar, Nubeqa, Stivarga, Vitrakvi, or Xofigo. Services are drug-specific and may include:

  • Oncology $0 Co-Pay Program assistance for eligible, commercially insured patients
  • Benefit verification/prior authorization denial and appeal information
  • Pharmacy coordination
  • Alternate coverage research for the uninsured and underinsured
  • Access and reimbursement support
  • Referrals to the Bayer US Patient Assistance Foundation for patients who are uninsured or underinsured and meet certain eligibility criteria.

For more information or to enroll your patient in Access Services by Bayer, call 800-288-8374 or see Table for drug-specific links.

Oncology $0 Co-Pay Program

The Oncology $0 Co-Pay Program allows patients to fill their prescriptions with no out-of-pocket costs for eligible, commercially insured patients.

To enroll your patient in the Oncology $0 Co-Pay Program, please see Table for drug-specific links.

Bayer US Patient Assistance Foundation

The Bayer US Patient Assistance Foundation is a charitable organization that helps eligible patients get their Bayer prescription medicine at no cost. Patients who have been prescribed Aliqopa, Nexavar, Nubeqa, Stivarga, or Vitrakvi.

TABLE Bayer Oncology Drugs

Drugs
Indications
Patient support programs

Drug
Aliqopa (copanlisib) for injection
Indications
Relapsed follicular lymphoma in adults after ≥2 systemic therapies
Patient support programs

Drug
Nexavar (sorafenib)
Indications
Unresectable hepatocellular carcinoma; advanced renal-cell carcinoma; locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
Patient support programs

Drug
Nubeqa (darolutamide)
Indications
Nonmetastatic castration-resistant prostate cancer metastatic, hormonesensitive prostate cancer in combination with docetaxel
Patient support programs

Drug
Stivarga (regorafenib)
Indications
Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an antiVEGF therapy, and, if RAS wild-type, an anti-EGFR therapy; treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor who have been previously treated with imatinib mesylate and sunitinib malate; patients with hepatocellular carcinoma who have been previously treated with sorafenib
Patient support programs

Drug
Vitrakvi (larotrectinib)
Indications
Treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or who have progressed following treatment, based on an FDA-approved test
Patient support program

Drug
Xofigo (radium Ra 223 dicholride) injection
Indications
Castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease
Patient support program